166 related articles for article (PubMed ID: 32003412)
21. Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer.
Chang D; Joseph DJ; Ebert MA; Galvão DA; Taaffe DR; Denham JW; Newton RU; Spry NA
J Med Imaging Radiat Oncol; 2014 Apr; 58(2):223-8. PubMed ID: 24118850
[TBL] [Abstract][Full Text] [Related]
22. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study.
Hansen PA; Dechet CB; Porucznik CA; LaStayo PC
PM R; 2009 Nov; 1(11):1019-24. PubMed ID: 19942188
[TBL] [Abstract][Full Text] [Related]
23. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review.
Bylow K; Mohile SG; Stadler WM; Dale W
Cancer; 2007 Dec; 110(12):2604-13. PubMed ID: 17960609
[TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial.
Nabid A; Carrier N; Vigneault E; Van Nguyen T; Vavassis P; Brassard MA; Bahoric B; Archambault R; Vincent F; Bettahar R; Wilke D; Souhami L
Eur J Cancer; 2021 Jan; 143():64-74. PubMed ID: 33279855
[TBL] [Abstract][Full Text] [Related]
25. Body composition, fatigue and exercise in patients with prostate cancer undergoing androgen-deprivation therapy.
Newton RU; Jeffery E; Galvão DA; Peddle-McIntyre CJ; Spry N; Joseph D; Denham JW; Taaffe DR
BJU Int; 2018 Dec; 122(6):986-993. PubMed ID: 29750398
[TBL] [Abstract][Full Text] [Related]
26. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
Ong WL; Foroudi F; Evans S; Millar J
BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
[TBL] [Abstract][Full Text] [Related]
27. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
28. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
Schmidt AL; Tucker MD; Bakouny Z; Labaki C; Hsu CY; Shyr Y; Armstrong AJ; Beer TM; Bijjula RR; Bilen MA; Connell CF; Dawsey SJ; Faller B; Gao X; Gartrell BA; Gill D; Gulati S; Halabi S; Hwang C; Joshi M; Khaki AR; Menon H; Morris MJ; Puc M; Russell KB; Shah NJ; Sharifi N; Shaya J; Schweizer MT; Steinharter J; Wulff-Burchfield EM; Xu W; Zhu J; Mishra S; Grivas P; Rini BI; Warner JL; Zhang T; Choueiri TK; Gupta S; McKay RR
JAMA Netw Open; 2021 Nov; 4(11):e2134330. PubMed ID: 34767021
[TBL] [Abstract][Full Text] [Related]
29. Resistance Exercise Training, a Simple Intervention to Preserve Muscle Mass and Strength in Prostate Cancer Patients on Androgen Deprivation Therapy.
Houben LHP; Beelen M; van Loon LJC; Beijer S
Int J Sport Nutr Exerc Metab; 2024 Mar; 34(2):122-134. PubMed ID: 38048764
[TBL] [Abstract][Full Text] [Related]
30. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
31. Utility of four sarcopenia criteria for the prediction of falls-related hospitalization in older Australian women.
Sim M; Prince RL; Scott D; Daly RM; Duque G; Inderjeeth CA; Zhu K; Woodman RJ; Hodgson JM; Lewis JR
Osteoporos Int; 2019 Jan; 30(1):167-176. PubMed ID: 30456572
[TBL] [Abstract][Full Text] [Related]
32. A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design.
Thorsen L; Nilsen TS; Raastad T; Courneya KS; Skovlund E; Fosså SD
BMC Cancer; 2012 Mar; 12():123. PubMed ID: 22458865
[TBL] [Abstract][Full Text] [Related]
33. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.
Galvão DA; Taaffe DR; Spry N; Newton RU
Prostate Cancer Prostatic Dis; 2007; 10(4):340-6. PubMed ID: 17486110
[TBL] [Abstract][Full Text] [Related]
34. Responsiveness to Resistance-Based Multimodal Exercise Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy.
Taaffe DR; Newton RU; Spry N; Joseph DJ; Galvão DA
J Natl Compr Canc Netw; 2019 Oct; 17(10):1211-1220. PubMed ID: 31590154
[TBL] [Abstract][Full Text] [Related]
35. Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study.
Rijksen BLT; Pos FJ; Hulshof MCCM; Vernooij RWM; Jansen H; van Andel G; Wijsman BP; Somford DM; Busstra MB; van Moorselaar RJA; Kaa CAH; van Leenders GJLH; Hamberg P; van den Berkmortel F; Fütterer JJ; Kiemeney LA; van Oort IM; Aben KKH
Eur Urol Focus; 2021 Mar; 7(2):332-339. PubMed ID: 31748122
[TBL] [Abstract][Full Text] [Related]
36. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation.
Nguyen QN; Levy LB; Lee AK; Choi SS; Frank SJ; Pugh TJ; McGuire S; Hoffman K; Kuban DA
Cancer; 2013 Sep; 119(18):3265-71. PubMed ID: 23798338
[TBL] [Abstract][Full Text] [Related]
38. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
[TBL] [Abstract][Full Text] [Related]
39. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
[TBL] [Abstract][Full Text] [Related]
40. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]